143 related articles for article (PubMed ID: 26406001)
1. Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Liu L; Sun L; Li C; Li X; Zhang Y; Yu Y; Xia W
Biomed Mater Eng; 2015; 26 Suppl 1():S2217-22. PubMed ID: 26406001
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
3. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
7. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
8. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir.
Syeed N; Husain SA; Sameer AS; Chowdhri NA; Siddiqi MA
Mutat Res; 2011 Feb; 707(1-2):1-8. PubMed ID: 21095196
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer].
Feng J; Hu LH; Lu J; Li YR; Xie F
Ai Zheng; 2009 Apr; 28(4):436-40. PubMed ID: 19622308
[TBL] [Abstract][Full Text] [Related]
10. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
Silva Soares EW; de Lima Santos SC; Bueno AG; Cavalli IJ; Cavalli LR; Fouto Matias JE; de Souza Fonseca Ribeiro EM
Cancer Genet Cytogenet; 2010 May; 199(1):24-30. PubMed ID: 20417865
[TBL] [Abstract][Full Text] [Related]
11. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
12. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
13. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Isaacs C; Cavalli LR; Cohen Y; Pennanen M; Shankar LK; Freedman M; Singh B; Liu M; Gallagher A; Rone JD; Dickson RB; Sidransky D; Haddad BR
Breast Cancer Res Treat; 2004 Mar; 84(2):99-105. PubMed ID: 14999140
[TBL] [Abstract][Full Text] [Related]
14. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
Chen Y; Zhou J; Xu Y; Li Z; Wen X; Yao L; Xie Y; Deng D
Cancer Sci; 2009 Sep; 100(9):1663-7. PubMed ID: 19522853
[TBL] [Abstract][Full Text] [Related]
16. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
Santos SC; Cavalli LR; Cavalli IJ; Lima RS; Haddad BR; Ribeiro EM
J Clin Pathol; 2004 Apr; 57(4):374-7. PubMed ID: 15047740
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Magdinier F; Ribieras S; Lenoir GM; Frappart L; Dante R
Oncogene; 1998 Dec; 17(24):3169-76. PubMed ID: 9872332
[TBL] [Abstract][Full Text] [Related]
19. Loss expression of active fragile sites genes associated with the severity of breast epithelial abnormalities.
Wang TT; Frezza EE; Ma R; Hu SY; Liu CZ; Zhang GY; Wachtel MS; Lü XM; Feng JB; Lü CX
Chin Med J (Engl); 2008 Oct; 121(20):1969-74. PubMed ID: 19080258
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
